Arca
Skip to content
Tools
Tools

Astrocytoma

Drug research and approvals for astrocytoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 319 studies of astrocytoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 5 approved and 2 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 319
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 5
  • EU medicines: 1

Recruiting now

Newest posted first, of 319 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 6

  • TemozolomideGlioblastoma · DNA inhibitor
  • BevacizumabGlioblastoma · Vascular endothelial growth factor A inhibitor
  • CarmustineGlioblastoma · Glutathione reductase inhibitor
  • EverolimusFK506-binding protein 1A inhibitor
  • VorasidenibIDH1/IDH2 inhibitor
  • TrametinibGlioblastoma · Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

Phase 3 12 of 27

  • LomustineGlioblastoma · DNA inhibitor
  • NivolumabGlioblastoma · Programmed cell death protein 1 inhibitor
  • CarboplatinGlioblastoma · DNA inhibitor
  • IpilimumabGlioblastoma · Cytotoxic T-lymphocyte protein 4 inhibitor
  • Cintredekin besudotoxGlioblastoma · Interleukin 13 receptor binding agent
  • CilengitideGlioblastoma · Integrin alpha-V/beta-3 antagonist
  • HydroxyureaGlioblastoma · Ribonucleoside-diphosphate reductase RR1 inhibitor
  • DianhydrogalactitolGlioblastoma · DNA cross-linking agent
  • Depatuxizumab mafodotinGlioblastoma · Epidermal growth factor receptor erbB1 binding agent
  • CediranibGlioblastoma · Stem cell growth factor receptor inhibitor
  • ImatinibGlioblastoma · Tyrosine-protein kinase ABL inhibitor
  • ChloroquineGlioblastoma · Ferriprotoporphyrin IX inhibitor

Phase 2 12 of 176

  • PembrolizumabGlioblastoma · Programmed cell death protein 1 inhibitor
  • IrinotecanGlioblastoma · DNA topoisomerase I inhibitor
  • DisulfiramGlioblastoma · Aldehyde dehydrogenase inhibitor
  • Aminolevulinic acidGlioblastoma · DNA inhibitor
  • MetforminGlioblastoma · Mitochondrial complex I (NADH dehydrogenase) inhibitor
  • SunitinibGlioblastoma · Macrophage colony stimulating factor receptor inhibitor
  • VorinostatGlioblastoma · Histone deacetylase 1 inhibitor
  • TemsirolimusGlioblastoma · FK506-binding protein 1A inhibitor
  • HiltonolGlioblastoma
  • CetuximabGlioblastoma · Epidermal growth factor receptor erbB1 inhibitor
  • ErlotinibGlioblastoma · Epidermal growth factor receptor erbB1 inhibitor
  • CatequentinibGlioblastoma · Vascular endothelial growth factor receptor 2 inhibitor

Phase 1 or earlier 12 of 133

How its trials ended

394 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 116 whose ending is known, 17% met their primary endpoint, 10% missed it and 72% stopped early.

  • Completed, result not reported15840%
  • Ongoing9023%
  • Stopped: other or unclear379%
  • Status unknown308%
  • Stopped: enrollment or feasibility226%
  • Met its primary endpoint205%
  • Stopped: sponsor or business decision174%
  • Missed its primary endpoint123%
  • Stopped: lack of efficacy41%
  • Stopped: funding31%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Mar 31, 2017A phase 3, randomized, open-label study to evaluate the efficacy and safety of eflornithine with lomustine compared to lomustine alone in patients with…EflornithineOrbus TherapeuticsOngoing
Aug 5, 2015Phase 2/3 randomized, open-label study of toca 511, a retrovial replicating vector, combined with toca fc versus standard of care in subjects undergoing…Toca 511/ Toca fcTocagenOngoing

FDA orphan designations

Approved first, then open designations, newest first
Aug 6, 2024VoranigoTreatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate…Servier Pharmaceuticals LLCApproved
Apr 10, 2018AfinitorFor the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated…Novartis Pharmaceuticals Corp.Approved
Apr 26, 2012AfinitorTreatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.Novartis Pharmaceuticals Corp.Approved
Oct 29, 2010AfinitorTreatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic…Novartis Pharmaceuticals Corp.Approved
Aug 11, 1999TemodarTreatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease…Schering-Plough Research InstituteApproved
Jul 24, 2019(R)-6-((3,3-difluoro-1-methylpiperidine-4-yl)oxy-N-(3-ethyny…Treatment of glioma (including glioblastoma and anaplastic astrocytoma)Wayshine Biopharm Inc.Designated
Feb 12, 1999Iodine I-131 radiolabeled chimeric MAb tumor necrosis…Treatment of glioblastoma multiforme and anaplastic astrocytoma.Peregrine Pharmaceuticals, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Sep 17, 2025VoranigoVorasidenib · orphanLes Laboratoires ServierEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.